NCT01825889View on ClinicalTrials.gov

A Study of Evacetrapib (LY2484595) in Participants With Severe Renal Impairment and in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

October 31, 2013

Study Completion Date

October 31, 2013

Conditions
Cardiovascular Disease
Interventions
DRUG

Evacetrapib

Trial Locations (3)

32806

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Orlando

33014

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Miami

55114

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saint Paul

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT01825889 - A Study of Evacetrapib (LY2484595) in Participants With Severe Renal Impairment and in Healthy Participants | Biotech Hunter | Biotech Hunter